<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403362</url>
  </required_header>
  <id_info>
    <org_study_id>HS-EPOP2b</org_study_id>
    <nct_id>NCT02403362</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis</brief_title>
  <official_title>A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney Disease Not Requiring Dialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety,efficacy， pharmacodynamics (PD), and
      pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic
      kidney disease (CKD) Who are not on dialysis
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieved a target hemoglobin response during the study</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>A target hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 gram per deciliter (g/dL) from baseline and a hemoglobin value ≥ 10.0 g/dL during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who response to study drug</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 gram per deciliter (g/dL) from baseline during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average reticulocytes change from baseline</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average hemoglobin change from baseline</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>EPO-018B 0.025 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO-018B 0.05 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO-018B 0.08 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO-018B</intervention_name>
    <arm_group_label>EPO-018B 0.025 mg/kg</arm_group_label>
    <arm_group_label>EPO-018B 0.05 mg/kg</arm_group_label>
    <arm_group_label>EPO-018B 0.08 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥18 and≤70.

          2. Chronic renal diseases stage 3 or 4 (estimated Glomerular Filtration Rate (eGFR)
             between 15 and 60 ml/min per 1.73 m2 using the CKD-EPI equation) and no expected need
             for dialysis during the study.

          3. Patients who have not received any erythropoietic agents within 6 weeks prior to the
             first study dose.

          4. Two hemoglobin values of ≥ 6.0 and &lt; 10.0 g/dL at Screening

          5. Patients with a transferrin saturation ≥ 20% or a ferritin ≥ 100 ng/mL. vitamin B12
             and folic acid level above lower limit of normal.

          6. Signed informed consent.

        Exclusion Criteria:

          1. Pregnant or lactating females.

          2. Red blood cell transfusion within 3 months prior to study drug administration.

          3. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule
             or to all parenteral iron supplementation products .

          4. Hemolytic syndromes or coagulation disorder.

          5. Hematological disease (including but not limited to myelodysplastic syndrome,
             hematological malignancy, hemoglobinopathy, pure red cell aplasia).

          6. Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid
             arthritis, systemic lupus erythematosus, etc.).

          7. C reactive Protein (CRP)level greater than 30 mg/L within the 4 weeks prior to study
             drug administration.

          8. Uncontrolled or symptomatic secondary hyperparathyroidism(iPTH&gt;500pg/ml).

          9. Poorly controlled hypertension within 2 weeks prior to study drug administration, per
             investigator's clinical judgment (e.g. systolic ≥ 160mm Hg, diastolic ≥ 100 mm Hg)

         10. Chronic congestive heart failure (New York Heart Association Class IV).

         11. Significant symptom within 6 months prior to study drug administration (e.g.
             myocardial infarction, serious or precarious coronary artery disease,stroke,
             respiratory disease, autoimmune disease, neuropathy, phrenopathy, hepatopathy
             including Active hepatitis B, Active hepatitis C, or ALT&gt; 3 x upper limit of normal
             (ULN), AST&gt; 3 x upper limit of normal (ULN), etc.).

         12. A positive test for HIV antibody.

         13. Tumor malignancy.

         14. Expected survival less than 12 months.

         15. Major surgery (may Massive bleeding) during the study.

         16. Expected conception within 4 Weeks after the end of the Study Treatment.

         17. The subject has participated in other clinical trial within the 6 weeks prior to study
             drug administration.

         18. Have any other condition or prior therapy that, in the investigator's opinion, would
             make the subject unsuitable for the study, or unable or unwilling to comply with the
             study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqing Yu</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqing Yu, PhD., M.D.</last_name>
    <phone>020-8755766-8802</phone>
    <email>yuxq@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqing Yu, PhD., M.D.</last_name>
      <phone>020-8755766-8802</phone>
      <email>yuxq@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

